A 76-Year-Old Man with Relapsed/Refractory Multiple Myeloma

David M. Dingli, MD, PhD, a hematologist at Mayo Clinic, as he discusses a challenging case of pentarefractory multiple myeloma in a 76-year-old patient and explores novel treatment options.

An exploration of the landscape of immunologic therapies and alternative approaches for relapsed/refractory multiple myeloma, including bispecific antibodies, XPO1 inhibitors, venetoclax, and more.

Expert perspective on teclistamab, a bispecific antibody, in the context of multiple myeloma treatment, discussing its potential benefits and associated considerations.

Insights into the use of bispecific antibodies, including talquetamab, and elranatamab, in treating relapsed/refractory multiple myeloma, discussing their efficacy and potential side effects.

David M. Dingli, MD, PhD, discusses the advantages and considerations of CAR T-cell therapy versus bispecific antibodies for relapsed/refractory multiple myeloma, helping patients make informed treatment decisions.

The importance of patient education, remote monitoring, and infection prophylaxis in the safe administration of bispecific antibody therapy for relapsed/refractory multiple myeloma.

Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.